EP Patent

EP1659175A1 — Alterations in seborrheic keratoses and their applications

Assigned to Centre National de la Recherche Scientifique CNRS · Expires 2006-05-24 · 20y expired

What this patent protects

The present invention relates to activated FGFR3 mutations in seborrheic keratoses and their applications for studying and treating seborrheic keratoses: use of epidermis lesion of a given transgenic animal as experimental model, treatment and composition for therapeutic and cosm…

USPTO Abstract

The present invention relates to activated FGFR3 mutations in seborrheic keratoses and their applications for studying and treating seborrheic keratoses: use of epidermis lesion of a given transgenic animal as experimental model, treatment and composition for therapeutic and cosmetic applications.

Drugs covered by this patent

Patent Metadata

Patent number
EP1659175A1
Jurisdiction
EP
Classification
—
Expires
2006-05-24
Drug substance claim
No
Drug product claim
No
Assignee
Centre National de la Recherche Scientifique CNRS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.